Today (March 3), Shenzhen Neptunus Bioengineering Co.Ltd(000078) ( Shenzhen Neptunus Bioengineering Co.Ltd(000078) , SZ) announced that the company is planning a major asset restructuring. This transaction does not constitute a restructuring and listing, and is still in the early contact stage; In addition, Shenzhen Neptunus Bioengineering Co.Ltd(000078) controlling shareholder Shenzhen Haiwang Group Co., Ltd. (hereinafter referred to as Haiwang Group) is planning Shenzhen Neptunus Bioengineering Co.Ltd(000078) mixed ownership reform, and plans to introduce strategic investors, which may involve the change of the actual controller of the company.
According to the 2021 annual performance forecast released by Shenzhen Neptunus Bioengineering Co.Ltd(000078) previously, the company expects the net profit attributable to the shareholders of the listed company to be 60-85 million yuan in 2021, turning loss into profit year-on-year, and – 289 million yuan in the same period of last year.
plans to plan major asset restructuring and mixed ownership reform
On March 3, Shenzhen Neptunus Bioengineering Co.Ltd(000078) announced that it planned to plan major asset restructuring and mixed ownership reform.
For the major asset reorganization, the company said that the matter is still in the early contact stage. According to the provisions of the measures for the administration of major asset reorganization of listed companies, if the matter is successfully implemented, the asset reorganization is expected to constitute a major asset reorganization, but the transaction does not constitute a re listing, will not lead to the change of control of the listed company, and does not constitute a related party transaction.
For the planning of mixed ownership reform, the company said that it had recently received a notice from the controlling shareholder Haiwang Group that it was planning Shenzhen Neptunus Bioengineering Co.Ltd(000078) mixed ownership reform and planned to introduce strategic investors. The matter may involve the change of the actual controller of the company and have a great impact on the company. According to the third quarter report of the company in 2021, Haiwang Group holds 44.22% of the shares of the listed company, and Zhang Simin is the actual controller of the listed company.
Shenzhen Neptunus Bioengineering Co.Ltd(000078) at the same time, it is disclosed that the approval of the company’s non-public offering of shares expires Shenzhen Neptunus Bioengineering Co.Ltd(000078) said that the company received the reply on approving Shenzhen Neptunus Bioengineering Co.Ltd(000078) non-public offering of shares issued by the CSRC on March 11, 2021, which approved that the company’s non-public offering of no more than 651 million shares was valid within 12 months from the date of approval of issuance (March 5, 2021) Shenzhen Neptunus Bioengineering Co.Ltd(000078) said that the company has been actively promoting the issuance of non-public shares after obtaining the approval. However, due to changes in the capital market environment, issuance timing and other reasons, the company failed to implement the non-public offering within the validity period of the approval, and the approval will automatically expire.
It is reported that Shenzhen Neptunus Bioengineering Co.Ltd(000078) originally intended to raise no more than 2.5 billion yuan, with an issue price of 384 yuan / share. It is planned to invest 1 billion yuan to raise funds to repay bank loans and another 1.5 billion yuan to supplement working capital.
2021 turn loss into profit
At present, Shenzhen Neptunus Bioengineering Co.Ltd(000078) has formed an industrial chain covering Pharmaceutical Research and development, pharmaceutical manufacturing and pharmaceutical commercial circulation. It is reported that the pharmaceutical business sector of the company mainly provides downstream customers such as hospitals, grass-roots medical institutions, drug retail institutions and distributors with the distribution and circulation of medical supplies such as drugs and medical devices and related extended value-added services.
In terms of business, the Shenzhen Neptunus Bioengineering Co.Ltd(000078) revenue is mainly concentrated in two parts: medical circulation and medical devices. According to the company’s 2021 interim report, the revenue of pharmaceutical circulation business and medical device business accounted for 75.44% and 22.59% respectively.
Recently, Shenzhen Neptunus Bioengineering Co.Ltd(000078) disclosed the performance forecast for 2021. The company expects the net profit attributable to the shareholders of the listed company to be 60 million yuan to 85 million yuan in 2021, turning losses into profits year-on-year, up from – 289 million yuan in the same period of last year. As for the performance changes, Shenzhen Neptunus Bioengineering Co.Ltd(000078) said that last year, the covid-19 pneumonia epidemic in China was controlled, the public medical institutions basically resumed the reception, the distribution business of the company’s subordinate business units to the public medical institutions returned to normal, and the company’s operating revenue increased compared with the same period of the previous year.
Shenzhen Neptunus Bioengineering Co.Ltd(000078) in the annual performance forecast for 2021, the company also said that according to relevant regulations, the company has conducted a preliminary impairment test on the goodwill formed by the acquisition of subsidiaries in the early stage. It is estimated that the goodwill impairment withdrawn in the current period is 170 million yuan to 210 million yuan. The provision for goodwill impairment is reduced compared with the same period of the previous year, resulting in the company’s performance turning loss into profit.
At the closing on the afternoon of March 3, Shenzhen Neptunus Bioengineering Co.Ltd(000078) reported 3.54 yuan / share, up 6.63% from the previous trading day
